Paclitaxel Versus Sirolimus. The Battle Is Still Ongoing

Journal of the American College of Cardiology

Volumn 53, Issue 8, 2009, Pages 665-666

  Stefanadis, Christodoulos ^a   Toutouzas, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cypher; drug eluting stents; stent thrombosis; Taxus

Indexed keywords

PACLITAXEL; RAPAMYCIN;

BARE METAL STENT; CORONARY STENT; DISEASE REGISTRY; DRUG ELUTING STENT; EDITORIAL; HUMAN; PRIORITY JOURNAL; RESTENOSIS; SAFETY; STENT THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; SIROLIMUS; TREATMENT OUTCOME;

EID: 60049093772     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.10.048     Document Type: Editorial

References (12)

1. Ellis S.G., Colombo A., Grube E., et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Schampaert E., Moses J.W., Schofer J., et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 (2006) 36-41
4. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
5. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
6. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
7. Kaltolft A., Jensen L.O., Maeng M., et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 53 (2009) 658-664
8. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
9. Galloe A.M., Thuesen L., Kelbaek H., et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 299 (2008) 409-416
10. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
11. Stefan J. SCAAR-Long-term mortality after drug-eluting stents in Sweden, an additional year of follow-up. Presented at: Congress of European Society of Cardiology 2007; Vienna (2007) September 2
12. Turco M.A., Ormiston J.A., Popma J.J., et al. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 49 (2007) 1676-1683